Katherine Stueland sold $1.1M of WGS
Chief Executive Officer at GeneDx Holdings Corp.. 11,637 shares at an average of $96.04, traded Mar 13, 2025, filed Mar 17, 2025.
Score components
- +25RoleCEO
- +25Trade size$1.1M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +4.0%, 3m -29.2%, 6m +29.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-008282, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 13, 2025 | SOpen-market sale Class A Common Stock | -1,078 | $89.44 | $96k | 6,674 | Mar 17, 2025 |
| Mar 16, 2025 | MOption exercise Class A Common Stock | +18,750 | $0.00 | $0 | 25,424 | Mar 17, 2025 |
| Mar 17, 2025 | SOpen-market sale Class A Common Stock | -10,559 | $96.71 | $1.0M | 14,865 | Mar 17, 2025 |
| Mar 26, 2024 | AGrant or award Restricted Stock Unitderivative | +320,000 | $0.00 | $0 | 320,000 | Mar 17, 2025 |
| Mar 15, 2025 | AGrant or award Restricted Stock Unitderivative | +47,684 | $0.00 | $0 | 47,684 | Mar 17, 2025 |
| Mar 16, 2025 | MOption exercise Restricted Stock Unitderivative | -18,750 | $0.00 | $0 | 150,000 | Mar 17, 2025 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 28Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $227k 3,729 shares | -9% | |
| 38Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $638k 10,501 shares | -9% | |
| 23Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $68k 1,266 shares | -3% | |
| 30Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $196k 3,639 shares | -4% | |
| 56Moderate | WGSbuy GeneDx Holdings Corp. | Casdin Capital, LLC director, owner | $11M 200,000 shares | +6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.